Evidence map›Paper›PMID 39467891›Full record

SynthesisNeurosurgical review2024

Application of radiomics for diagnosis, subtyping, and prognostication of medulloblastomas: a systematic review.

Maryam Fotouhi, Ataollah Shahbandi, Fardin Samadi Khoshe Mehr, Mahdi Mohammadzadeh Shahla, Seyed Mobin Nouredini, Samuel B Kankam, MirHojjat Khorasanizadeh, Lola B Chambless

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maryam FotouhiAdvanced Diagnostic and Interventional Radiology Research Center (ADIR), Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ataollah ShahbandiSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-1042-8580
Fardin Samadi Khoshe MehrMedical Physics and Engineering Department, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi Mohammadzadeh ShahlaSchool of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Seyed Mobin NourediniFaculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Samuel B KankamDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA.
MirHojjat KhorasanizadehDepartment of Neurosurgery, Mount Sinai Hospital, Icahn School of Medicine, New York, NY, USA. mkhorasaniza@mcw.edu.
Lola B ChamblessDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Applications of radiomics for clinical management of medulloblastomas are expanding. This systematic review aims to aggregate and overview the current role of radiomics in the diagnosis, subtyping, and prognostication of medulloblastomas. The present systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed/MEDLINE were searched using a standardized search term. Articles found within the database from the inception until November 2022 were considered for screening. Retrieved records were screened independently by two authors based on their titles and abstracts. The full text of selected articles was reviewed to finalize the eligibility. Due to the heterogeneity of included studies, no formal data synthesis was conducted. Of the 249 screened citations, 21 studies were included and analyzed. Radiomics demonstrated promising performance for discriminating medulloblastomas from other posterior fossa tumors, particularly ependymomas and pilocytic astrocytomas. It was also efficacious in determining the subtype (i.e., WNT+, SHH+, group 3, and group 4) of medulloblastomas non-invasively. Regarding prognostication, radiomics exhibited some ability to predict overall survival and progression-free survival of patients with medulloblastomas. Our systematic review revealed that radiomics represents a promising tool for diagnosis and prognostication of medulloblastomas. Further prospective research measuring the clinical value of radiomics in this setting is warranted.

Indexed as

Cerebellar NeoplasmsMedulloblastomaHumansMagnetic Resonance ImagingPrognosisRadiomicsBrain tumorComputer visionDeep learningMedulloblastomasRadiomics

Identifiers

PMID39467891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.